Mark Scheunemann is currently an Executive Rare Disease Specialist at AstraZeneca, where they partner with healthcare professionals to enhance the diagnosis and treatment of hereditary transthyretin amyloidosis and have notably increased regional sales by 200%. Previously, Mark worked in various roles in the pharmaceutical industry, including membership development at IDOC and completed leadership development programs at Boehringer Ingelheim. Mark is also pursuing a Bachelor's degree in Business Administration and Management at Western Connecticut State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices